ライフサイエンスコーパス: kidney transplantation

1 in waiting times persist for deceased donor kidney transplantation.

2 address geographic disparities in access to kidney transplantation.

3 derived, he proceeded to simultaneous liver-kidney transplantation.

4 ay contribute to disparities in living donor kidney transplantation.

5 r, often into older age, and commonly pursue kidney transplantation.

6 rding the type of CMV preventive strategy in kidney transplantation.

7 ma release assay to predict CMV infection in kidney transplantation.

8 ministration is unfeasible in deceased-donor kidney transplantation.

9 development of injury and cytoprotection in kidney transplantation.

10 t preservation fluid predictive of DGF after kidney transplantation.

11 , three of whom underwent simultaneous heart-kidney transplantation.

12 ism was intentionally induced at the time of kidney transplantation.

13 ng DSA monitoring may improve outcomes after kidney transplantation.

14 he T cell-mediated immune response following kidney transplantation.

15 tion of a dn DSA, 65.3 months (median) after kidney transplantation.

16 he incidence of delayed graft function after kidney transplantation.

17 th impaired long-term clinical outcome after kidney transplantation.

18 patients and in the allocation of organs for kidney transplantation.

19 associated with increased risk of DGF after kidney transplantation.

20 ly assess virus transmission in living-donor kidney transplantation.

21 eGFR, initiation of maintenance dialysis, or kidney transplantation.

22 clinical importance in intensive care and in kidney transplantation.

23 e value for delayed graft function following kidney transplantation.

24 as well as in the immunological response to kidney transplantation.

25 ading cause of morbidity and mortality after kidney transplantation.

26 ney disease (CKD) arose from observations in kidney transplantation.

27 KV) is a significant cause of nephropathy in kidney transplantation.

28 sure (eLAP), and mortality in candidates for kidney transplantation.

29 donors and recipients was a breakthrough in kidney transplantation.

30 can ancestry improves outcomes and safety in kidney transplantation.

31 ocioeconomic status (SES) and outcomes after kidney transplantation.

32 ction of a dnDSA, 65.3 months (median) after kidney transplantation.

33 r donor kidney quality and function in human kidney transplantation.

34 sitization, after desensitization, and after kidney transplantation.

35 asures, that improve long-term outcome after kidney transplantation.

36 ociated with a lower likelihood of accessing kidney transplantation.

37 ropriate to refer an affected individual for kidney transplantation.

38 atients were excluded from consideration for kidney transplantation.

39 clinical trials of Treg therapy in liver and kidney transplantation.

40 cies that attempt to maximize survival after kidney transplantation.

41 etter understanding of racial disparities in kidney transplantation.

42 tized patients an opportunity for successful kidney transplantation.

43 disease with a high rate of recurrence after kidney transplantation.

44 8-year-old boy with previous living-related kidney transplantation.

45 anocytic squamous cell carcinoma (SCC) after kidney transplantation.

46 verity of infections in the first year after kidney transplantation.

47 l gastrectomy was evaluated for living donor kidney transplantation.

48 hort of 538 patients in the first year after kidney transplantation.

49 kidney transplantation who received a second kidney transplantation.

50 adverse cardiovascular outcomes in pediatric kidney transplantation.

51 ing these core outcome domains for trials in kidney transplantation.

52 iated with increased risk of mortality after kidney transplantation.

53 lume, VA centers offer excellent outcomes in kidney transplantation.

54 tation of core outcome domains for trials in kidney transplantation.

55 nt cause of loss of allograft function after kidney transplantation.

56 ed protein 4 Ig) is an emerging treatment in kidney transplantation.

57 ht induce cross-dressing following liver and kidney transplantation.

58 titative assessment of microperfusion during kidney transplantation.

59 function in donation after circulatory death kidney transplantation.

60 d as a reason for organ refusal in pediatric kidney transplantation.

61 de novo donor-specific antibody (DSA) after kidney transplantation.

62 infection-related morbidity and mortality in kidney transplantation.

63 ng, we applied this novel technique to human kidney transplantation.

64 sociated with higher risk of mortality after kidney transplantation.

65 ling solution to improve equity in access to kidney transplantation.

66 ted with inferior posttransplant outcomes in kidney transplantation.

67 ies in CKD are reversible and normalize with kidney transplantation.

68 potentially improve CMV-related outcomes in kidney transplantation.

69 easures that improve long-term outcome after kidney transplantation.

70 sure (eLAP), and mortality in candidates for kidney transplantation.

71 invasively detect acute rejection (AR) after kidney transplantation.

72 on, graft rejection, and graft failure after kidney transplantation.

73 ciency and pharmacotherapy initiation before kidney transplantation.

74 reduce disparities and equilibrate access to kidney transplantation.

75 a risk factor for acute kidney injury after kidney transplantation.

76 However, little data are available on kidney transplantation.

77 ible approach to treat DGF in deceased donor kidney transplantation.

78 15 to October 2018, included 128 consecutive kidney transplantations.

79 aiting list was 0.54% (95% CI 0.40-0.67) for kidney transplantation, 0.49% (0.36-0.62) for heart, 0.1

80 n within a 2-year follow-up was higher after kidney transplantation (20%) than in KTCs (5.5%) (P = .0

81 This study analyzed 499 kidney transplantations, 50% of which were performed wit

82 required reconstruction more often with left kidney transplantation (67.6% vs 32.4%, P = .003).

83 equired reconstruction more often with right kidney transplantation (72.5% vs 27.5%, P < .001), and t

84 splantation was 93.5% (95% CI 81.0-97.9) for kidney transplantation, 80.6% (63.6-90.3) for heart, 27.

85 > 80%, DSA+ = 50 versus DSA- = 40) received kidney transplantation after DES with IVIG + rituximab +

86 ADPKD) than by lower rates of deceased donor kidney transplantation after waitlisting (rates were onl

87 stenosis are often considered ineligible for kidney transplantation, although kidney transplantation

88 -related nephrotoxicity, and developments in kidney transplantation among HIV-positive individuals.

89 oss is a primary endpoint in many studies in kidney transplantation and a broad spectrum of risk fact

90 n important short-term outcome to monitor in kidney transplantation and clinical trials.

91 e present the first reported experience with kidney transplantation and donation in transgender patie

92 eports of the application of NMP in clinical kidney transplantation and each uses different approach

93 inhibitors (PPIs) are frequently used after kidney transplantation and have been associated with inc

94 lain racial/ethnic disparities in receipt of kidney transplantation and may mask the actual magnitude

95 rt to follow up LTBI status in patients with kidney transplantation and shows its higher prevalence a

96 Fourteen (31%) patients had undergone kidney transplantation and six patients (13%) had underg

97 We enrolled patients who underwent kidney transplantation and were actively followed up in

98 Animals underwent kidney transplantation and were treated with tacrolimus

99 re (defined as the initiation of dialysis or kidney transplantation) and death.

100 9), controlling for age, sex, race, previous kidney transplantation, and donor type.

101 nal tolerance has been achieved in liver and kidney transplantation, and some intestinal transplant p

102 cardinal causes of late allograft loss after kidney transplantation, and there is great need for noni

103 who had CKD stage 5 at presentation received kidney transplantation; and 1 patient required further h

104 The maternofetal outcomes in patients with kidney transplantation are comparable with those of nont

105 al and economic consequences of cancer after kidney transplantation are incompletely defined.

106 ive graft tissue viability assessment before kidney transplantation are lacking.

107 cy of everolimus-based immunosuppression for kidney transplantation are lacking.

108 a has gained attention recently, but data in kidney transplantation are lacking.

109 urrent trends in cardiovascular events after kidney transplantation are poorly understood.

110 fied critically important outcome domains in kidney transplantation based on the shared priorities of

111 -inhibitor free immunosuppressive therapy in kidney transplantation but is associated with a higher a

112 New-onset diabetes is common after kidney transplantation but the benefit of lifestyle inte

113 ds effectively combats acute rejection after kidney transplantation, but at the cost of substantial s

114 important in clinical decision-making around kidney transplantation, but is difficult using available

115 Tac) is an effective anti-rejection agent in kidney transplantation, but its off-target effects make

116 New-onset diabetes is common after kidney transplantation, but the benefit of lifestyle int

117 Mortality risk after kidney transplantation can vary significantly during the

118 In this prospective study, we enrolled kidney transplantation candidates (KTCs) and recipients

119 ipients (SRTR) data to identify 92 081 adult kidney transplantation candidates who were offered a DCD

120 f glomerulonephritis that often recurs after kidney transplantation causing severe graft injury and o

121 At 5 and 10 years after kidney transplantation, chronic histologic changes such

122 nosuppressive regimen for combined islet and kidney transplantation (CIKTx) in nonhuman primates.

123 Combined liver-kidney transplantation (CLKT) improves survival for live

124 Combined liver-kidney transplantation (CLKT) improves survival for live

125 Although cardiac evaluation before kidney transplantation commonly focuses on coronary arte

126 ) and Hispanic patients have lower access to kidney transplantation compared to non-Hispanic whites (

127 e to antibody-mediated rejection (AMR) after kidney transplantation, compared to one desensitized ani

128 a donation after circulatory death model of kidney transplantation comparing standard cold storage w

129 Because cognition improves after kidney transplantation, comparing these brain abnormalit

130 t maintenance immunosuppression regimens for kidney transplantation, concerns about toxicity have mad

131 s) (95% confidence intervals [CI]) for first kidney transplantation, controlling for year, demographi

132 n the field of viral hepatitis and liver and kidney transplantation convened a meeting to review curr

133 hnic minorities have lower rates of deceased kidney transplantation (DDKT) and living donor kidney tr

134 F) remains a major concern in deceased donor kidney transplantation (DDKT).

135 d racial and sex disparities in living donor kidney transplantation do not appear to be related to ne

136 Before kidney transplantation, donors and recipients are routin

137 Morbid obesity is a barrier to kidney transplantation due to inferior outcomes, includi

138 After kidney transplantation, early readmission is independent

139 In kidney transplantation, evaluating mismatches of HLA epl

140 We examined referral for kidney transplantation evaluation and start of the evalu

141 sEVs released shortly after liver, but not kidney, transplantation exhibit immunoinhibitory effects

142 tigen-matched, sibling donor bone marrow and kidney transplantation for ESRD due to multiple myeloma.

143 trategies involving combined bone marrow and kidney transplantation for patients with and without an

144 Disparities that affect equity in access to kidney transplantation for patients with kidney failure

145 tified all patients who underwent LSG before kidney transplantation from 2011-2016 (n = 20).

146 d enrolled 63 patients, of whom 30 underwent kidney transplantation from an HCV-viremic deceased dono

147 tal-body irradiation, underwent combined HCT/kidney transplantation from haploidentical donors; graft

148 neered simultaneous hematopoietic cell (HCT)/kidney transplantation from HLA-identical related donors

149 eactive antibody (cPRA) >=50% that underwent kidney transplantation from June 2013 to December 2016 i

150 s with a baseline cPRA >= 50% that underwent kidney transplantation from June 2013 to December 2016 i

151 In the context of kidney transplantation, genomic incompatibilities betwee

152 In pediatric kidney transplantation, graft survival of kidneys from d

153 Robotic kidney transplantation group had a significantly higher

154 in consideration the possibility of a living-kidney transplantation, had experienced persistent micro

155 in consideration the possibility of a living-kidney transplantation, had experienced persistent micro

156 Kidney transplantation has become a routine procedure in

157 ligible for kidney transplantation, although kidney transplantation has been acknowledged as the best

158 the incidence of cardiovascular events after kidney transplantation has changed from 1994 to 2009.

159 The gap between supply and demand in kidney transplantation has led to increased use of margi

160 redict poorer 2-year survival outcomes after kidney transplantation have been identified in this larg

161 uppression, graft and patient outcomes after kidney transplantation have improved considerably.

162 ge renal disease who require dialysis and/or kidney transplantation, have some of the highest rates o

163 Following isolated kidney transplantation he would remain C3 deficient with

164 zation has enabled incompatible living donor kidney transplantation (ILDKT) across HLA/ABO barriers,

165 unosuppression and underimmunosuppression in kidney transplantation, impacting short- and long-term o

166 ntibody (cPRA) are associated with increased kidney transplantation in 100% cPRA patients.

167 NT-proBNP on arrival at the hospital before kidney transplantation in 658 KTR between January 1995 a

168 day -7 (n = 4, group C) before living donor kidney transplantation in addition to post-transplantati

169 cts of HOPE on the immune response following kidney transplantation in an allogeneic rodent model.

170 aim of this study was to examine outcomes of kidney transplantation in APRT deficiency patients.

171 site for dialysis-treated patients to access kidney transplantation in Canada, is a subjective proces

172 The clinical outcomes of kidney transplantation in patients with aortoiliac steno

173 Current data regarding the outcome of kidney transplantation in patients with familial Mediter

174 Kidney transplantation in patients with TASC II A/B is f

175 Kidney transplantation in recipients with a previous mal

176 ges have affected outcomes for candidates of kidney transplantation in the United States.

177 the circulation shortly after liver, but not kidney, transplantation in association with the release

178 assing a spectrum of renal dysfunction after kidney transplantation including those who may or may no

179 The lack of organs for kidney transplantation is a growing concern.

180 mmalian target of rapamycin inhibitors after kidney transplantation is associated with a concentratio

181 segmental glomerular sclerosis (FSGS) after kidney transplantation is challenging with unpredictable

182 Induction therapy in deceased donor kidney transplantation is costly, with wide discrepancy

183 Deceased-donor kidney transplantation is frequently performed at weeken

184 alovirus (CMV) immune-risk stratification in kidney transplantation is highly needed to establish gui

185 mediated rejection (ABMR) classification for kidney transplantation is interpreted in practice and af

186 The waiting list for kidney transplantation is long.

187 with a history of serious fall injury before kidney transplantation is unknown.

188 In contrast, living donor kidney transplantation is used frequently in the United

189 In kidney transplantation, it has been suggested that femal

190 usion until transplant: 69 with simultaneous kidney transplantation (KT) (at time of LT, group 1) and

191 Therefore, it is likely that kidney transplantation (KT) candidates with recurrent fa

192 African Americans have lower rates of kidney transplantation (KT) compared to Whites, even aft

193 with end-stage renal disease is longer after kidney transplantation (KT) compared with those remainin

194 African Americans (AA) have lower rates of kidney transplantation (KT) compared with Whites (WH), e

195 The old-for-old allocation policy used for kidney transplantation (KT) has confirmed the survival b

196 mmalian target of rapamycin inhibitors after kidney transplantation (KT) have not been fully addresse

197 tandard of care immunosuppressive regimen in kidney transplantation (KT) includes a combination of my

198 Kidney transplantation (KT) is the treatment of choice f

199 Kidney transplantation (KT) may restore fertility in chr

200 d in less growth retardation after pediatric kidney transplantation (KT) over time.

201 Several kidney transplantation (KT) prediction models for patien

202 for differences in the Veterans Affairs (VA) Kidney Transplantation (KT) Program.

203 The incidence of pregnancy in kidney transplantation (KT) recipients is increasing.

204 ospital readmission and mortality risk among kidney transplantation (KT) recipients.

205 Subclinical rejection (SCR) screening in kidney transplantation (KT) using protocol biopsies and

206 needed to monitor stable patients following kidney transplantation (KT), as subclinical rejection, c

207 to understand the impact of the epidemic on kidney transplantation (KT), at both the national and ce

208 actors for invasive aspergillosis (IA) after kidney transplantation (KT), we conducted a systematic s

209 fections remain a major threat to successful kidney transplantation (KT).

210 cidence of fractures in the first year after kidney transplantation (KT).

211 negative donor to HIV+ recipient (HIV D-/R+) kidney transplantation (KT).

212 onveterans, the impact of rurality status on kidney transplantation (KTP) access among veterans is un

213 e of BK polyomavirus (BKPyV) infection after kidney transplantation (KTx), including development of B

214 remains associated with poor outcomes after kidney transplantation (kTx).

215 dney transplantation (DDKT) and living donor kidney transplantation (LDKT) in the United States.

216 he presence of sex disparity in living donor kidney transplantation (LDKT) remains controversial.

217 sought to assess likelihood of living donor kidney transplantation (LDKT) within a single-center kid

218 ociated with worse outcomes after live donor kidney transplantation (LDKT), and prior work suggests t

219 dress patient-level barriers to living-donor kidney transplantation (LDKT), centers have implemented

220 an important tool to facilitate living donor kidney transplantation (LDKT).

221 esult in sustained increases in living-donor kidney transplantation (LDKT).

222 Allogeneic kidney transplantation led to death in all untreated rec

223 g these brain abnormalities before and after kidney transplantation may identify potential reversibil

224 sponses and graft pathology, we used a mouse kidney transplantation model that subjected MHC-mismatch

225 Using a murine kidney transplantation model, we examined the effects on

226 The lack of new drug development in kidney transplantation necessitated repurposing drugs in

227 ents of the United States who are in need of kidney transplantation occasionally contract with living

228 In addition to status of kidney transplantation, old age, no BCG vaccination, and

229 importance of outcome domains for trials in kidney transplantation on a 9-point Likert scale and pro

230 erial spin labeling to assess the effects of kidney transplantation on cerebral blood flow and magnet

231 es in LUTM at 10 years were similar to other kidney transplantations on native bladders.

232 ienced progressive CKD (defined as dialysis, kidney transplantation, or a 40% decline from postnephre

233 e (defined as dialysis for at least 90 days, kidney transplantation, or confirmed sustained eGFR <15m

234 r >=90 days, chronic dialysis for >=90 days, kidney transplantation, or death from kidney failure) in

235 history of pretransplant melanoma, previous kidney transplantation, or transplantation after 2012 or

236 Differences in kidney transplantation outcomes across GN subtypes have

237 We sought to compare kidney transplantation outcomes between Veterans Affairs

238 titutes of Health-sponsored "APOL1 Long-term Kidney Transplantation Outcomes" Network will determine

239 ams to identify a target group for improving kidney transplantation outcomes.

240 Kidney transplantation patients with estimated glomerula

241 Allocation for pediatric deceased-donor kidney transplantation (pDDKT) in the United States now

242 Data of all first kidney transplantation performed before 30 years of age

243 Robotic kidney transplantation permits transplantation in extrem

244 phic disparities in access to deceased donor kidney transplantation persist in the United States unde

245 n the adjusted probability of deceased donor kidney transplantation persist under KAS, even between c

246 aphics, comorbidities, dialysis vintage, and kidney transplantation, PH was associated with twice the

247 raphics, comorbidities, dialysis vintage and kidney transplantation, PH was associated with twice the

248 ith adverse patient and graft outcomes after kidney transplantation, pilot data suggest that PH may i

249 lude that, in this nonhuman primate model of kidney transplantation, PRCL-02 demonstrated evidence of

250 liver transplantation or combined liver and kidney transplantation prior to the visit revealing a wi

251 , blood group, renal replacement time, prior kidney transplantation, race, gender, diabetes, and tran

252 Reduced kidney transplantation rates among comparator groups wer

253 Whether kidney transplantation rates differ by glomerulonephriti

254 es for all clinical stakeholders to increase kidney transplantation rates, and reduce total costs of

255 lysis facilities have historically had lower kidney transplantation rates, but it is unknown if the p

256 use a large cohort of Veterans Affairs (VA) kidney transplantation recipients to assess the risk of

257 own encouraging results for the treatment of kidney transplantation recipients with focal segmental g

258 of transplantation in 19 450 deceased donor kidney transplantation recipients with Medicare as prima

259 Following successful kidney transplantation, recipients usually regain fertil

260 CKD, liver retransplantation associated with kidney transplantation (ReLT-KT) might be necessary.

261 berculosis infection (LTBI) in patients with kidney transplantation remain unclear.

262 Treatment decisions in kidney transplantation requires patients and clinicians

263 s for hemodialysis, peritoneal dialysis, and kidney transplantation, respectively.

264 s for hemodialysis, peritoneal dialysis, and kidney transplantation, respectively.

265 disease leads to a growing waiting list for kidney transplantation resulting from the scarcity of ki

266 zation in pediatric blood group incompatible kidney transplantation results in excellent outcomes wit

267 une responses, clinical use of belatacept in kidney transplantation revealed a substantially high inc

268 uture efforts aimed to improve outcome after kidney transplantation should align with the relative we

269 Breastfeeding should be accepted after kidney transplantation since infant immunosuppressive dr

270 mented, the proportion of simultaneous liver-kidney transplantation (SLKT) has increased significantl

271 ion immunosuppression for simultaneous liver/kidney transplantation (SLKT).

272 herapy at 3 months) after simultaneous liver-kidney transplantation (SLKT).

273 Successful simultaneous pancreas-kidney transplantation (SPK) improves quality-of-life an

274 Simultaneous pancreas and kidney transplantation (SPKT) is an effective treatment

275 national Standardized Outcomes in Nephrology-Kidney Transplantation stakeholder consensus workshops i

276 DGF is a relevant problem after kidney transplantation; sufficient microperfusion of the

277 s a leading cause of allograft failure after kidney transplantation, the cellular and molecular proce

278 e countries, thus enabling them to receive a kidney transplantation they otherwise could not afford.

279 are new trials in autoimmunity and heart and kidney transplantation to determine effectiveness of inh

280 ildren were randomized at 4 to 6 weeks after kidney transplantation to switch to everolimus with redu

281 In mouse kidney transplantation, treatment with a CD47-blocking a

282 After kidney transplantation, uncontrolled BK polyomavirus (BK

283 dren with steroid-resistant NS who underwent kidney transplantation using next-generation sequencing.

284 luation processes to determine candidacy for kidney transplantation, variability in graft failure exi

285 rn holds for living donor and deceased donor kidney transplantation, varies by facility ownership, or

286 dialysis to placement on the deceased donor kidney transplantation waiting list, receipt of a living

287 Access to kidney transplantation was defined as time from initiati

288 Complete suspension of live donor kidney transplantation was reported by 71.8% and live do

289 requent, some restrictions to deceased donor kidney transplantation were reported by 84.0% and deceas

290 Risk factors for kidney transplantation were unilateral nephrectomy (HR 4

291 HD occurring in recipients of pancreas after kidney transplantation, which were diagnosed at 5.5 and

292 We investigated 375 deceased donor kidney transplantations, which had DSA assignment by sin

293 squamous cell carcinoma (SCC) after a first kidney transplantation who received a second kidney tran

294 Kidney transplantation with low-level DSA with or withou

295 (NSAID) use is recommended to be avoided in kidney transplantation, with a paucity of studies assess

296 mulative percentage of patients referred for kidney transplantation within 1 year of dialysis at the

297 calculated the probability of deceased donor kidney transplantation within 3 years of wait listing us

298 chronic dialysis) and listing or receipt of kidney transplantation within 5 years was examined in in

299 se patients and allowed them to benefit from kidney transplantation without an increased risk of oppo

300 e agent mycophenolate is used extensively in kidney transplantation, yet dosing strategy applied vari